These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29044643)

  • 21. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.
    Hostler CJ; Chen LF
    Expert Opin Pharmacother; 2013 Aug; 14(11):1529-36. PubMed ID: 23683070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
    Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fidaxomicin Compared With Oral Vancomycin for the Treatment of Severe
    Summers BB; Yates M; Cleveland KO; Gelfand MS; Usery J
    Hosp Pharm; 2020 Aug; 55(4):268-272. PubMed ID: 32742016
    [No Abstract]   [Full Text] [Related]  

  • 26. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS; Juang P
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
    Ford DC; Schroeder MC; Ince D; Ernst EJ
    Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
    Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is fidaxomicin worth the cost? An economic analysis.
    Bartsch SM; Umscheid CA; Fishman N; Lee BY
    Clin Infect Dis; 2013 Aug; 57(4):555-61. PubMed ID: 23704121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.
    Heimann SM; Vehreschild JJ; Cornely OA; Wisplinghoff H; Hallek M; Goldbrunner R; Böttiger BW; Goeser T; Hölscher A; Baldus S; Müller F; Jazmati N; Wingen S; Franke B; Vehreschild MJ
    Infection; 2015 Dec; 43(6):707-14. PubMed ID: 26123227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB
    J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: A multicenter retrospective study of inpatients, 2009-2011.
    Magee G; Strauss ME; Thomas SM; Brown H; Baumer D; Broderick KC
    Am J Infect Control; 2015 Nov; 43(11):1148-53. PubMed ID: 26521932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
    Weiss K; Allgren RL; Sellers S
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
    Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.